Defining effective treatment for latent tuberculosis infection

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

One of the keys to decreasing the incidence of active tuberculosis (TB) is preventing reactivation by aggressively treating latent TB infection. The American Thoracic Society and the CDC endorse 2 regimens using isoniazid (INH) and 1 regimen using rifampin. A 9-month regimen of INH is optimal for most patients. However, the drug is associated with mild hepatotoxicity and hepatitis. If aminotransferase levels are 3 to 5 times higher than normal or the patient has signs and symptoms such as nausea, vomiting, anorexia, persistently dark urine, jaundice, malaise, unexplained fever for more than 3 days, or right upper quadrant tenderness, INH should be discontinued. A daily dose of rifampin (600 mg in adults and 10 to 20 mg/kg in children) is reserved for persons exposed to patients with INH-resistant and rifampin-sensitive disease.

Original languageEnglish (US)
Pages (from-to)488-495
Number of pages8
JournalJournal of Respiratory Diseases
Volume25
Issue number11
StatePublished - Nov 2004

Fingerprint

Latent Tuberculosis
Rifampin
Isoniazid
Anorexia
Centers for Disease Control and Prevention (U.S.)
Transaminases
Jaundice
Nausea
Hepatitis
Signs and Symptoms
Vomiting
Tuberculosis
Fever
Therapeutics
Urine
Incidence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Defining effective treatment for latent tuberculosis infection. / Boyars, Michael; Mercado, Anita.

In: Journal of Respiratory Diseases, Vol. 25, No. 11, 11.2004, p. 488-495.

Research output: Contribution to journalArticle

@article{e653d84f8d5a44fcba4d259bb19f1c60,
title = "Defining effective treatment for latent tuberculosis infection",
abstract = "One of the keys to decreasing the incidence of active tuberculosis (TB) is preventing reactivation by aggressively treating latent TB infection. The American Thoracic Society and the CDC endorse 2 regimens using isoniazid (INH) and 1 regimen using rifampin. A 9-month regimen of INH is optimal for most patients. However, the drug is associated with mild hepatotoxicity and hepatitis. If aminotransferase levels are 3 to 5 times higher than normal or the patient has signs and symptoms such as nausea, vomiting, anorexia, persistently dark urine, jaundice, malaise, unexplained fever for more than 3 days, or right upper quadrant tenderness, INH should be discontinued. A daily dose of rifampin (600 mg in adults and 10 to 20 mg/kg in children) is reserved for persons exposed to patients with INH-resistant and rifampin-sensitive disease.",
author = "Michael Boyars and Anita Mercado",
year = "2004",
month = "11",
language = "English (US)",
volume = "25",
pages = "488--495",
journal = "Journal of Respiratory Diseases - For Pediatricians",
issn = "0194-259X",
publisher = "Cliggott Publishing Co.",
number = "11",

}

TY - JOUR

T1 - Defining effective treatment for latent tuberculosis infection

AU - Boyars, Michael

AU - Mercado, Anita

PY - 2004/11

Y1 - 2004/11

N2 - One of the keys to decreasing the incidence of active tuberculosis (TB) is preventing reactivation by aggressively treating latent TB infection. The American Thoracic Society and the CDC endorse 2 regimens using isoniazid (INH) and 1 regimen using rifampin. A 9-month regimen of INH is optimal for most patients. However, the drug is associated with mild hepatotoxicity and hepatitis. If aminotransferase levels are 3 to 5 times higher than normal or the patient has signs and symptoms such as nausea, vomiting, anorexia, persistently dark urine, jaundice, malaise, unexplained fever for more than 3 days, or right upper quadrant tenderness, INH should be discontinued. A daily dose of rifampin (600 mg in adults and 10 to 20 mg/kg in children) is reserved for persons exposed to patients with INH-resistant and rifampin-sensitive disease.

AB - One of the keys to decreasing the incidence of active tuberculosis (TB) is preventing reactivation by aggressively treating latent TB infection. The American Thoracic Society and the CDC endorse 2 regimens using isoniazid (INH) and 1 regimen using rifampin. A 9-month regimen of INH is optimal for most patients. However, the drug is associated with mild hepatotoxicity and hepatitis. If aminotransferase levels are 3 to 5 times higher than normal or the patient has signs and symptoms such as nausea, vomiting, anorexia, persistently dark urine, jaundice, malaise, unexplained fever for more than 3 days, or right upper quadrant tenderness, INH should be discontinued. A daily dose of rifampin (600 mg in adults and 10 to 20 mg/kg in children) is reserved for persons exposed to patients with INH-resistant and rifampin-sensitive disease.

UR - http://www.scopus.com/inward/record.url?scp=14144249252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14144249252&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 488

EP - 495

JO - Journal of Respiratory Diseases - For Pediatricians

JF - Journal of Respiratory Diseases - For Pediatricians

SN - 0194-259X

IS - 11

ER -